


PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 1733.1068-008		APPLICATION NO. 10/758,717	
		FIRST NAMED INVENTOR James R. Dasch, <i>et al.</i>		FILING DATE January 16, 2004	
		EXAMINER Not Assigned		CONFIRMATION NO. 6559	
				GROUP 1654	

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
<i>JA</i>	AA	4,746,654	05/24/88	Breliere, <i>et al.</i>
<i>JA</i>	AB	4,922,007	05/01/90	Kieczkowski, <i>et al.</i>
<i>JA</i>	AC	5,019,651	05/28/91	Kieczkowski
<i>JA</i>	AD	5,196,409	03/23/93	Breuer, <i>et al.</i>
<i>JA</i>	AE	5,312,954	05/17/94	Breuer, <i>et al.</i>
<i>JA</i>	AF	5,412,141	05/02/95	Nugent
<i>JA</i>	AG	5,618,563	04/08/97	Berde, <i>et al.</i>
<i>JA</i>	AH	5,700,485	12/23/97	Berde, <i>et al.</i>
<i>JA</i>	AI	5,885,973	03/23/99	Papapoulos, <i>et al.</i>
<i>JA</i>	AJ	6,080,779	06/27/00	Gasper, <i>et al.</i>
<i>JA</i>	AK	6,117,856	09/12/00	Binderman, <i>et al.</i>
<i>JA</i>	AA2	6,162,929	12/19/00	Foricher, <i>et al.</i>
<i>JA</i>	AB2	6,165,513	12/26/00	Dansereau, <i>et al.</i>
<i>JA</i>	AC2	3,523,906	08/11/70	Vrancken, <i>et al.</i>
<i>JA</i>	AD2	3,691,090	09/12/72	Kitajima, <i>et al.</i>
<i>JA</i>	AE2	3,737,337	06/05/73	Schnoring, <i>et al.</i>
<i>JA</i>	AF2	3,891,570	06/24/75	Fukushima, <i>et al.</i>
<i>JA</i>	AG2	3,960,757	06/01/76	Morishita, <i>et al.</i>
<i>JA</i>	AH2	4,327,039	04/27/82	Blum, <i>et al.</i>
<i>JA</i>	AI2	4,389,330	06/21/83	Tice, <i>et al.</i>
<i>JA</i>	AJ2	4,705,651	11/10/87	Staibano
<i>JA</i>	AK2	5,091,400	05/28/91	Gombotz, <i>et al.</i>
<i>JA</i>	AA3	5,583,122	12/10/96	Benedict, <i>et al.</i>
<i>JA</i>	AB3	5,654,010	08/05/97	Johnson, <i>et al.</i>
<i>JA</i>	AC3	5,656,297	08/12/97	Bernstein, <i>et al.</i>
<i>JA</i>	AD3	5,667,808	09/16/97	Johnson, <i>et al.</i>

EXAMINER <i>Jeffrey E. Russell</i>	DATE CONSIDERED <i>March 28, 2005</i>
---------------------------------------	--

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION July 1, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 1733.1068-008		APPLICATION NO. 10/758,717	
	FIRST NAMED INVENTOR James R. Dasch, <i>et al.</i>		FILING DATE January 16, 2004	
	EXAMINER Not Assigned		CONFIRMATION NO. 6559	GROUP 1654

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
JSN	AE3	5,674,534	10/07/97	Zale, <i>et al.</i>
JSN	AF3	5,711,968	01/27/98	Tracy, <i>et al.</i>
JSN	AG3	5,716,644	02/10/98	Zale, <i>et al.</i>
JSN	AH3	5,922,253	07/13/99	Herbert, <i>et al.</i>
JSN	AI3	5,916,597	06/29/99	Lee, <i>et al.</i>
JSN	AJ3	5,773,477	06/30/98	MacLean, <i>et al.</i>
JSN	AK3	5,861,168	01/19/99	Cooke, <i>et al.</i>
JSN	AA4	6,399,592 B1	06/04/02	Whiteford
JSN	AB4	6,558,702	05/06/03	Dasch, <i>et al.</i>

425/52
 424/501
 424/487
 424/497
 261/5
 424/501
 514/648
 424/424
 514/10
 424/484

EXAMINER <i>Jeffrey E. Russell</i>	DATE CONSIDERED <i>March 28, 2005</i>
------------------------------------	---------------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION July 1, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 1733.1068-008	APPLICATION NO. 10/758,717	
	FIRST NAMED INVENTOR James R. Dasch, <i>et al.</i>	FILING DATE January 16, 2004	
	EXAMINER Not Assigned	CONFIRMATION NO. 6559	GROUP 1654

FOREIGN PATENT DOCUMENTS					Class / Subclass	
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
AL	WO 97/07788	03/97	Alkermes Controlled Therapeutics, Inc.			
AM	EP 709 085 A1	05/96	Takeda Chemical Industries, Ltd.			
AN						
AO						
AP						
AQ						
AL2						
AM2						
AN2						
AO2						
AP2						
AQ2						
AL3						
AM3						
AN3						
AO3						
AP3						
AQ3						
AL4						
AM4						
AN4						
AO4						
AP4						
AQ4						
AL5						












EXAMINER Jeffrey E. Russel	DATE CONSIDERED March 28, 2005
--------------------------------------	--

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION July 1, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 1733.1068-008	APPLICATION NO. 10/758,717	
	FIRST NAMED INVENTOR James R. Dasch, <i>et al.</i>	FILING DATE January 16, 2004	
	EXAMINER Not Assigned	CONFIRMATION NO. 6559	GROUP 1654

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
JR	AR	Dunn, C.J., <i>et al.</i> , "Demonstration of Novel Anti-Arthritic and Anti-Inflammatory Effects of Diphosphonates," <i>Journal of Pharmacology and Experimental Therapeutics</i> , 266(3):1691-1698 (1993).
JR	AS	Van Gelder, J. M., <i>et al.</i> , "In Vitro and in Vivo Effects of Tetrakisphosphonates on Bone Resorption, Tumor Osteolysis, Ectopic Calcification, and Macrophages," <i>Journal of Pharmaceutical Sciences</i> , 86(3):283-289 (1997).
JR	AT	Nugent, R.A., <i>et al.</i> , "Pyrazoline Bisphosphonate Esters as Novel Antiinflammatory and Antiarthritic Agents," <i>J. Med. Chem.</i> , 36:134-139 (1993)
JR	AU	D'Souza, M.J., <i>et al.</i> , "Macrophage Depletion by Albumin Microencapsulated Clodronate: Attenuation of Cytokine Release in Macrophage-Dependent Glomerulonephritis," <i>Drug Development and Industrial Pharmacy</i> , 25(5):591-596 (1999).
JR	AV	Nugent, R.A., <i>et al.</i> , "Carbonyl-Containing Bisphosphonate Esters as Novel Antiinflammatory and Antiarthritic Agents," <i>J. Med. Chem.</i> , 37:4449-4454 (1994).
JR	AW	Hyvönen, P.M., and Kowolik, M.J., "Influence of Dichloromethylene Bisphosphonate on the <i>in vitro</i> Phagocytosis of Hydroxyapatite Particles by Rat Peritoneal Exudate Cells: An Electron Microscopic and Chemiluminescence Study," <i>Annals of the Rheumatic Diseases</i> , 51:203-209 (1992).
JR	AX	Barbier, A., <i>et al.</i> , "Studies on the Chronic Phase of Adjuvant Arthritis: Effect of SR 41319, A New Diphosphonate," <i>Annals of the Rheumatic Diseases</i> , 45:67-74 (1986).
JR	AY	Van Rooijen, N., <i>et al.</i> , "Transient Suppression of Macrophage Functions by Liposome-Encapsulated Drugs," <i>Trends in Biotechnology</i> , 15:178-185 (1997).
JR	AZ	Reginster, J.Y., <i>et al.</i> , "Prevention of Postmenopausal Bone Loss by Tiludronate," <i>The Lancet</i> , pp. 1469-1471, (1989, December 23/30).
JR	AR2	Bijvoet, O.L.M., <i>et al.</i> , "APD in Paget's Disease of Bone," <i>Arthritis and Rheumatism</i> , 23(10):1193-1204 (1980).
JR	AS2	Francis, M.D., <i>et al.</i> , "The Effects of Disodium Ethane-1-Hydroxy-1, 1-Diphosphonate on Adjuvant Induced Arthritis in Rats," <i>Calc. Tiss. Res.</i> , 9(2):109-121 (1972).
JR	AT2	Flora, L., "Comparative Antiinflammatory and Bone Protective Effects of Two Diphosphonates in Adjuvant Arthritis," <i>Arthritis and Rheumatism</i> , 22(4):340-346 (1979).

EXAMINER Jeffrey E. Russel	DATE CONSIDERED Mar 28, 2005
-------------------------------	---------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION July 1, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 1733.1068-008	APPLICATION NO. 10/758,717	
	FIRST NAMED INVENTOR James R. Dasch, <i>et al.</i>	FILING DATE January 16, 2004	
	EXAMINER Not Assigned	CONFIRMATION NO. 6559	GROUP 1654

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AU2	Francis, M.D., <i>et al.</i> , "NE-58095: A Diphosphonate Which Prevents Bone Erosion and Preserves Joint Architecture in Experimental Arthritis," <i>Int. J. Tiss. React.</i> , XI(5):239-252 (1989).
	AV2	Daoud, A.S., <i>et al.</i> , "The Effect of Ethane-1-Hydroxy-1,1-Diphosphonate (EHDP) on Necrosis of Atherosclerotic Lesions," <i>Atherosclerosis</i> , 67:41-48 (1987).
	AW2	Camilleri, J.P., <i>et al.</i> , "The Effect of Free and Liposome-Encapsulated Clondronate on the Hepatic Mononuclear Phagocyte System in the Rat," <i>Clin. Exp. Immunol.</i> , 99(2):269-275 (1995).
	AX2	Biewenga, J., <i>et al.</i> , "Macrophage Depletion in the Rat After Intraperitoneal Administration of Liposome-Encapsulated Clodronate: Depletion Kinetics and Accelerated Repopulation of Peritoneal and Omental Macrophages by Administration of Freund's Adjuvant," <i>Cell Tissue Res.</i> , 280(1):189-196 (1995).
	AY2	Van Rooijen, N., <i>et al.</i> , "Depletion and Repopulation of Macrophages in Spleen and Liver of Rat After Intravenous Treatment with Liposome-Encapsulated Dichloromethylene Diphosphonate," <i>Cell Tissue Res.</i> , 260(2):215-222 (1990).
	AZ2	Delemarre, F.G.A., <i>et al.</i> , "Repopulation of Macrophages in Popliteal Lymph Nodes of Mice After Liposome-Mediated Depletion," <i>Journal of Leukocyte Biology</i> , 47(3):251-257 (1990).
	AR3	Storm, T., <i>et al.</i> , "Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal Osteoporosis," <i>New England Journal of Medicine</i> , 322(18):1265-1271 (1990).
	AS3	Ralston, S.H., <i>et al.</i> , "A Double Blind Placebo-Controlled Trial of Diphosphonate (APD) Therapy in Rheumatoid Arthritis-Preliminary Results," <i>Calcified Tissue</i> , Supplement to Vol. 42, p. A23, Abstract No. 90 (1988).
	AT3	Markusse, H.M., <i>et al.</i> , "Bisphosphonates in Collagen Arthritis," <i>Rheumatology International</i> , 9(6):281-283 (1990).
	AU3	Vyavahare, <i>et al.</i> , "Synergism of Calcium-Ethanehydroxybisphosphonate (CaEHBP) and FeCl ₃ : Controlled Release Polymers for Preventing Calcification of Bioprosthetic Aortic Wall," <i>Journal of Controlled Release</i> , 34:97-108, (1995).
	AV3	Weidenauer, U., <i>et al.</i> , "Microencapsulation of hydrophilic drug substances I using biodegradable polyesters. Part 1: Evaluation of different techniques for the encapsulation of Pamidronate di-sodium salt", <i>J. Microencapsulation</i> , 20(4): 509-524 (2003).

EXAMINER Jeffrey E. Russel	DATE CONSIDERED March 28, 2005
-------------------------------	-----------------------------------

